<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04149951</url>
  </required_header>
  <id_info>
    <org_study_id>UCD2</org_study_id>
    <nct_id>NCT04149951</nct_id>
  </id_info>
  <brief_title>Effect of VeSTAL Device in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Randomized, Double Blind Controlled Trial to Evaluate Efficacy of Vestibular Nerve Stimulation (VeNS), With Lifestyle Modification, Compared to Control and Lifestyle Modification, as a Means of Lowering HbA1c in Adults With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurovalens Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Compliance Solutions Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Exploristics Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurovalens Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve&#xD;
      stimulation (VeNS), together with a lifestyle modification program, as a method of reducing&#xD;
      HbA1c, as compared to a sham control with both study arms incorporating a lifestyle&#xD;
      modification program.&#xD;
&#xD;
        -  Allocation: Randomized&#xD;
&#xD;
        -  Endpoint classification: Efficacy Study&#xD;
&#xD;
        -  Intervention Model: Parallel Assignment in 1:1 active to control allocation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an ongoing and worsening problem with type 2 diabetes mellitus (DM) in the&#xD;
      developed, and much of the developing world. Although it has long been realized that Western&#xD;
      diets that are rich in sugar and fat play an important role in this, it has only recently&#xD;
      been realized that exposure to these diets, particularly in childhood, can damage the part of&#xD;
      the brain that determines how much fat there is in the body, which may well play a role in&#xD;
      the development of metabolic syndrome, deranged glycemic control and type 2 DM. It is&#xD;
      believed, based on animal and human work, that VeNS pushes the set-point for fat downwards to&#xD;
      cause fat loss, possibly because this indicates to the brain a state of increased physical&#xD;
      activity. VeNS may additionally have other direct, yet to be quantified, effects on glycemic&#xD;
      control.&#xD;
&#xD;
      The sponsors have unpublished pilot data from Dr Saisailesh Kumar at RDG Medical College in&#xD;
      India that show an improvement in glycemic control can be achieved by one hour a day of VeNS&#xD;
      over a three month period. Both groups received a hypocaloric diet tailored to diabetics. The&#xD;
      aim of this study is to determine whether this effect can be replicated in a slightly larger&#xD;
      European based population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Actual">January 22, 2021</completion_date>
  <primary_completion_date type="Actual">January 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment in 1:1 active to control allocation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated Hemoglobin (HbA1c)</measure>
    <time_frame>4 months</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in mean weight loss between the active-product and sham-treated groups.</measure>
    <time_frame>4 months</time_frame>
    <description>Grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily caloric intake</measure>
    <time_frame>4 months</time_frame>
    <description>Two day 24 hour recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>4 months</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>4 months</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference</measure>
    <time_frame>4 months</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>4 months</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>4 months</time_frame>
    <description>Rating from -1 to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cravings</measure>
    <time_frame>4 months</time_frame>
    <description>Rating from -1 to 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fullness</measure>
    <time_frame>4 months</time_frame>
    <description>Rating from -1 to 1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mentorship support usage</measure>
    <time_frame>4 months</time_frame>
    <description>Average hours per week</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose response analysis</measure>
    <time_frame>4 months</time_frame>
    <description>Average hours per week</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to active device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized to sham device use plus lifestyle modification (500kcal deficit hypocaloric diet and 150 min of exercise per week for each subject).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vestal Device</intervention_name>
    <description>Vestibular nerve stimulator</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo device</intervention_name>
    <description>Sham nerve stimulator</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 DM&#xD;
&#xD;
          2. HbA1c ≥7.0% and ≤10.0%&#xD;
&#xD;
          3. If on oral anti-diabetic medication should be stable dosage regime last 3 months&#xD;
&#xD;
          4. Males or Females. Note females of child-bearing potential must have a negative urine&#xD;
             pregnancy test.&#xD;
&#xD;
          5. 18-80 years of age inclusive on starting the study.&#xD;
&#xD;
          6. Ability and willingness to complete all study visits and procedures; in particular an&#xD;
             agreement to engage with: trying to use the device on a daily basis; the hypocaloric&#xD;
             diet weight loss program; and this provided weight loss support and mentoring.&#xD;
&#xD;
          7. Agreement not to use of prescription, or over-the-counter, weight loss preparations&#xD;
             for the duration of the trial.&#xD;
&#xD;
          8. Agreement not to start smoking tobacco or marijuana for the duration of the study.&#xD;
&#xD;
          9. Access to Wi-Fi (to connect iPod to internet)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of vestibular dysfunction or other inner ear disease as indicated by the&#xD;
             screening questions.&#xD;
&#xD;
          2. History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis)&#xD;
             affecting the skin behind the ears.&#xD;
&#xD;
          3. History of weight loss device implantation (e.g. VBloc Maestro or Abiliti).&#xD;
&#xD;
          4. Use of a non-invasive weight loss device (e.g. Modius)&#xD;
&#xD;
          5. Hypothyroidism requiring current treatment with levothyroxine (e.g. Levo-T, Synthroid,&#xD;
             Thyroxine) (Other thyroid disorder patients on stable treatment for at least 3 months&#xD;
             are acceptable).&#xD;
&#xD;
          6. Other endocrinological causes of weight gain (e.g. Cushing's disease, Cushing's&#xD;
             syndrome or acromegaly)&#xD;
&#xD;
          7. Previous diagnosis of HIV infection or AIDS (HIV is known to cause a vestibular&#xD;
             neuropathy which would prevent VeNS from working).&#xD;
&#xD;
          8. Diagnosis of liver, kidney or heart failure.&#xD;
&#xD;
          9. Tobacco or marijuana smoking in the 3 months before starting and for the duration of&#xD;
             the study.&#xD;
&#xD;
         10. Known genetic cause of type 2 DM (e.g., Prader-Willi Syndrome).&#xD;
&#xD;
         11. Current, active member of an organized weight loss program.&#xD;
&#xD;
         12. Diagnosis of Type 1 DM.&#xD;
&#xD;
         13. Use of insulin.&#xD;
&#xD;
         14. Diagnosis of epilepsy or use of anti-epileptic medication within 3 months of starting&#xD;
             the study (e.g. for the treatment of peripheral neuropathy)&#xD;
&#xD;
         15. Use of oral or intravenous corticosteroid medication within 3 months of starting the&#xD;
             study.&#xD;
&#xD;
         16. Use of the beta-blockers within 3 months of starting the study.&#xD;
&#xD;
         17. Current alterations in treatment regimens of anti-depressant medication for whatever&#xD;
             reason (including tricyclic antidepressants) (Note: stable treatment regimen for prior&#xD;
             6 months acceptable).&#xD;
&#xD;
         18. A myocardial infarction within the preceding year.&#xD;
&#xD;
         19. A history of stroke or severe head injury (as defined by a head injury that required&#xD;
             craniotomy or endotracheal intubation). (In case this damaged the neurological&#xD;
             pathways involved in vestibular stimulation).&#xD;
&#xD;
         20. Presence of permanently implanted battery powered medical device or stimulator (e.g.,&#xD;
             pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator&#xD;
             etc.).&#xD;
&#xD;
         21. Untreated severe depression, schizophrenia, substance abuse, and eating disorder.&#xD;
&#xD;
         22. Current participant in another clinical trial.&#xD;
&#xD;
         23. Have a family member who is currently participating or is planning to participate in&#xD;
             this study.&#xD;
&#xD;
         24. Pregnancy.&#xD;
&#xD;
         25. Blood transfusion within 4 months, or need for recurrent transfusions.&#xD;
&#xD;
         26. Hemolytic anemias including sickle cell, thalassemia and autoimmune varieties.&#xD;
&#xD;
         27. Hemochromatosis.&#xD;
&#xD;
         28. Use of dietary/ herbal supplements to assist with diabetic control.&#xD;
&#xD;
         29. History of migraine headaches.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carel Le Roux, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

